FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 1, 2003, Pages 63-71

  Kitagawa, Yoshimasa ^a   Sano, Kazuo ^a   Nishizawa, Sadahiko ^a   Nakamura, Mikiko ^a   Ogasawara, Toshiyuki ^a   Sadato, Norihiro ^a   Yonekura, Yoshiharu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

FDG PET; Head and neck; MIB 1; PCNA; Proliferation

Indexed keywords

CARBOPLATIN; CYCLINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; MONOCLONAL ANTIBODY KI 67; PIRARUBICIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HEAD CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE REGRESSION; NECK CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0038546395     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0978-z     Document Type: Article

References (31)

1. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495.
2. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN, Wolf AP, Zabinski SV. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
3. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32:623-648.
4. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30:150-185.
5. Kitagawa Y, Sadato N, Azuma H, Ogasawara T, Yoshida M, Ishii Y, Yonekura Y. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy for head and neck neoplasms. J Nucl Med 1999; 40:1132-1137.
6. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32:1323-1329.
7. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995; 60:1348-1352.
8. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33:325-329.
9. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61:1776-1781.
10. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32:1548-1555.
11. Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18]fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J Otorhinolaryngol Relat Spec 2001; 63:307-313.
12. Hermanek P, Sobin LH, eds. UICC: TNM classification of malignant tumours, 4th edn. Berlin Heidelberg New York: Springer, 1987.
13. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for staging of cancer, 4th edn. Philadelphia: Lippincott, 1992.
14. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
15. Shimosato Y, Oboshi S, Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971; 1: 19-35.
16. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
17. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35:1398-1406.
18. Sano K, Yoshida S, Ninomiya H, Ikeda H, Ueno K, Sekine J, Iwamoto H, Uehara M, Inokuchi T. Assessment of growth potential by MIB-1 immunohistochemistry in ameloblastic fibroma and related lesions of the jaws compared with ameloblastic fibrosarcoma. J Oral Pathol Med 1998; 27:59-63.
19. Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, Gerdes J. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993; 68:629-636.
20. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36:252-258.
21. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, Seki H, Nambu Y, Tonami H, Yamamoto I. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41:85-92.
22. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, Wood DE. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6: 3837-3844.
23. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
24. Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, Bocking A, Bull U, Gilsbach JM. PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl 1996; 65: 108-111.
25. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42:721-725.
26. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414-419.
27. Ito K, Kato T, Ohta T, Tadokoro M, Yamada T, Ikeda M, Nishino M, Ishigaki T, Gambhir S. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996; 23:1372-1377.
28. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, Isomura T, Ito S, Nishino M, Ishigaki T. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995; 22:32-39.
29. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, Honda T, Inokuma T, Katsushima S, Ohshio G, Imamura M, Konishi J. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39:1727-1735.
30. Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V, Heiss WD. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993; 79:853-858.
31. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 174:1005-1008.